ProLynx LLC has developed a technology platform that overcomes major limitations of conjugates currently used for half-life extension. The technology uses sets of novel linkers that are pre-programmed to cleave at different rates to allow the controlled, predictable and sustained release of native, active drugs – peptides, proteins and small molecules – from circulating and semi-solid macromolecular conjugates. 

 Using our technology, we can sustain desired steady-state levels of drugs for predictable periods of weeks to months. ​​About the cover art click here.

“Everything should be made as simple as possible, but not simpler”
Albert Einstein